p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia

被引:0
作者
Malisic, E. [1 ]
Jankovic, R. [1 ]
Slavkovic, D. [1 ]
Milovic-Kovacevic, M. [2 ]
Radulovic, S. [1 ]
机构
[1] Inst Oncol & Radiol Serbia, Dept Expt Oncol, Belgrade 11000, Serbia
[2] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade 11000, Serbia
来源
JOURNAL OF BUON | 2010年 / 15卷 / 01期
关键词
codon; 72; polymorphism; ovarian carcinoma; p53; mutations; EARLY-STAGE; PROGNOSTIC-SIGNIFICANCE; TP53; MUTATIONS; CANCER; CHEMOTHERAPY; EXPRESSION; VARIANTS; BREAST; MODEL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Ovarian cancer is the leading cause of death from gynecological malignancies. The early stages of this disease are asymptomatic and more than 75% of the cases are diagnosed with regional or distant metastases. p53 gene is frequently mutated in some histological subtypes of ovarian carcinomas. The role of p53 mutations and polymorphic variant of codon 72 in the prognosis of disease is still unclear The aim of this study was to determine the frequency of p53 mutations and polymorphic variants of codon 72 among ovarian carcinoma patients and to correlate them with clinicopathological characteristics of disease. Methods: 54 ovarian carcinoma patients were included in the study. DNA was isolated from tumor tissue by the salting-out method. p53 mutations in exons 4-8 were detected by PCR-SSCP (polymerase chain reaction - single-stranded conformational polymorphism) electrophoresis. Codon 72 polymorphism was assessed by RFLP (restriction fragment-length polymorphism) method. Results: p53 mutations were present in 11 out of 54 patients (20.4%). Twenty-four patients (44.4%) exhibited Arg/Arg, 24 patients (44.4%) Arg/Pro and 6 patients (11.2%) Pro/Pro genotype of 72 codon polymorphism. Correlations between p53 mutations and various clinicopathological characteristics were not found However we observed that the frequency of Pro/Pro genotype was increasing with higher histological grade as well as in advanced compared to localized disease, but without statistical significance. Distribution of p53 gene mutations between Pro/Pro genotype and Arg/Pro plus Arg/Arg genotypes was not statistically significant. Conclusion: Our study suggests that Pro/Pro genotype of 72 codon polymorphism could be an independent prognostic marker in ovarian carcinomas.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 28 条
[1]   P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women [J].
Agorastos, T ;
Masouridou, S ;
Lambropoulos, AF ;
Chrisafi, S ;
Miliaras, D ;
Pantazis, K ;
Constantinides, TC ;
Kotsis, A ;
Bontis, I .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2004, 13 (04) :277-280
[2]   Rescuing the function of mutant p53 [J].
Bullock, AN ;
Fersht, A .
NATURE REVIEWS CANCER, 2001, 1 (01) :68-76
[3]  
CARLSON KJ, 1994, ANN INTERN MED, V121, P124, DOI 10.7326/0003-4819-121-2-199407150-00009
[4]   Ovarian cancer [J].
Colombo, Nicoletta ;
Van Gorp, Toon ;
Parma, Gabriella ;
Amant, Frederic ;
Gatta, Gemma ;
Sessa, Cristiana ;
Vergote, Ignace .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (02) :159-179
[5]   p53 mutation does not affect prognosis in ovarian epithelial malignancies [J].
Fallows, S ;
Price, J ;
Atkinson, RJ ;
Johnston, PG ;
Hickey, I ;
Russell, SEH .
JOURNAL OF PATHOLOGY, 2001, 194 (01) :68-75
[6]   Mutational spectrum of p53 mutations in primary breast and ovarian tumors [J].
Feki, A ;
Irminger-Finger, I .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 52 (02) :103-116
[7]  
Gadducci A, 2006, ANTICANCER RES, V26, P687
[8]   Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas [J].
Galic, Vijaya ;
Willner, Julia ;
Wollan, Melissa ;
Garg, Ruchi ;
Garcia, Rochelle ;
Goff, Barbara A. ;
Gray, Heidi J. ;
Swisher, Elizabeth M. .
GENES CHROMOSOMES & CANCER, 2007, 46 (03) :239-247
[9]  
Guan X, 1998, Zhonghua Fu Chan Ke Za Zhi, V33, P165
[10]   CA125 response: Can it replace the traditional response criteria in ovarian cancer? [J].
Guppy, AE ;
Rustin, GJS .
ONCOLOGIST, 2002, 7 (05) :437-443